Literature DB >> 22384784

In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors.

Justin D Lutz1, Nina Isoherranen.   

Abstract

INTRODUCTION: Predictions of drug-drug interactions (DDIs) are commonly performed for single inhibitors, but interactions involving multiple inhibitors also frequently occur. Predictions of such interactions involving stereoisomer pairs, parent/metabolite combinations and simultaneously administered multiple inhibitors are increasing in importance. This review provides the framework for predicting inhibitory DDIs of multiple inhibitors with any combination of reversible inhibition mechanism. AREAS COVERED: The review provides an overview of the reliability of the in vitro determined reversible inhibition mechanism. Furthermore, the article provides a method to predict DDIs for multiple reversible inhibitors that allows substituting the inhibition constant (K(i)) with an inhibitor affinity (IC(50)) value determined at S << K(M). EXPERT OPINION: A better understanding and the prediction methods of DDIs, resulting from multiple inhibitors, are important. The inhibition mechanism of a reversible inhibitor is often equivocal across studies and unreliable. Determination of the K(i) requires the assignment of reversible inhibition mechanism but in vitro-to-in vivo prediction of DDI risk can be achieved for multiple inhibitors from estimates of the inhibitor affinity (IC(50)) only, regardless of the inhibition mechanism.

Mesh:

Substances:

Year:  2012        PMID: 22384784     DOI: 10.1517/17425255.2012.667801

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  6 in total

1.  Physiologically Based Pharmacokinetic Model of All-trans-Retinoic Acid with Application to Cancer Populations and Drug Interactions.

Authors:  Jing Jing; Cara Nelson; Jisun Paik; Yoshiyuki Shirasaka; John K Amory; Nina Isoherranen
Journal:  J Pharmacol Exp Ther       Date:  2017-03-08       Impact factor: 4.030

2.  An S-warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator.

Authors:  Ken Grime; Rikard Pehrson; Pär Nordell; Michael Gillen; Wolfgang Kühn; Timothy Mant; Marie Brännström; Petter Svanberg; Barry Jones; Clive Brealey
Journal:  Br J Clin Pharmacol       Date:  2016-10-13       Impact factor: 4.335

3.  In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation.

Authors:  Jennifer E Sager; Sasmita Tripathy; Lauren S L Price; Abhinav Nath; Justine Chang; Alyssa Stephenson-Famy; Nina Isoherranen
Journal:  Biochem Pharmacol       Date:  2016-11-09       Impact factor: 5.858

4.  Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.

Authors:  Andrea R Masters; Brandon T Gufford; Jessica Bo Li Lu; Ingrid F Metzger; David R Jones; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2016-06-02       Impact factor: 4.030

5.  Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.

Authors:  Justin D Lutz; Brooke M VandenBrink; Katipudi N Babu; Wendel L Nelson; Kent L Kunze; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2013-06-19       Impact factor: 3.922

6.  Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate.

Authors:  Jill C Chappell; P Kellie Turner; Y Anne Pak; James Bacon; Alan Y Chiang; Jane Royalty; Stephen D Hall; Palaniappan Kulanthaivel; Joseph V Bonventre
Journal:  Clin Pharmacol Ther       Date:  2018-12-30       Impact factor: 6.875

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.